ArticleMedical oncology (Northwood, London, England)2012

The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.

Grzegorz Helbig et al.PubMed ↗Publisher ↗

No numbers read from the abstract.